Compare PEBO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | OMER |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.8M |
| IPO Year | N/A | 2009 |
| Metric | PEBO | OMER |
|---|---|---|
| Price | $34.18 | $11.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $33.50 | $32.50 |
| AVG Volume (30 Days) | 370.5K | ★ 2.1M |
| Earning Date | 01-20-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | ★ $417,146,000.00 | N/A |
| Revenue This Year | $17.29 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.21 | $2.95 |
| 52 Week High | $34.25 | $17.65 |
| Indicator | PEBO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 68.11 | 42.33 |
| Support Level | $31.42 | $10.55 |
| Resistance Level | $34.25 | $12.18 |
| Average True Range (ATR) | 0.77 | 0.67 |
| MACD | 0.20 | -0.21 |
| Stochastic Oscillator | 88.39 | 20.66 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.